Please note: In order to keep Hive up to date and provide users with the best features, we are no longer able to fully support Internet Explorer. The site is still available to you, however some sections of the site may appear broken. We would encourage you to move to a more modern browser like Firefox, Edge or Chrome in order to experience the site fully.

Generic Drugs : The Pay-for-Delay Problem, PDF eBook

Generic Drugs : The Pay-for-Delay Problem PDF

Edited by Christina M Curtin

PDF

Please note: eBooks can only be purchased with a UK issued credit card and all our eBooks (ePub and PDF) are DRM protected.

Description

Brand-name pharmaceutical companies can delay generic competition that lowers prices by agreeing to pay a generic competitor to hold its competing product off the market for a certain period of time.

These so-called "pay-for-delay" agreements have arisen as part of patent litigation settlement agreements between brand-name and generic pharmaceutical companies. "Pay-for-delay" agreements are "win-win" for the companies: brand name pharmaceutical prices stay high, and the brand and generic share the benefits of the brand's monopoly profits.

Consumers lose, however: they miss out on generic prices that can be as much as 90 percent less than brand prices.

For example, brand-name medication that costs $300 per month, might be sold as a generic for as little as $30 per month.

This book examines the "pay-for-delay' program and how drug company pay-offs cost consumers billions.

Information

Information